This HTML5 document contains 100 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n9http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q73599594
rdf:type
wikibase:Item
schema:description
наукова стаття, опублікована у квітні 2000 wetenschappelijk artikel artículu científicu espublizáu n'abril de 2000 wüsseschaftlicher Artikel, wo im April 2000 veröffentlicht worden isch im April 2000 veröffentlichter wissenschaftlicher Artikel scientific article published on 01 April 2000 article scientifique publié en 2000
p:P577
wds:Q73599594-F947369C-2C65-43D2-AB9F-ABC351703A18
wdt:P577
2000-04-01T00:00:00Z
p:P407
wds:Q73599594-54BBA4E7-73BD-41A7-B77C-282920A78F8C
wdt:P407
wd:Q1860
p:P2860
wds:Q73599594-D4CC07F8-F798-40A1-AA83-282CC5D8CF0E wds:Q73599594-DEC88385-DC15-4E3D-9B5F-5EFBEEC7E35D wds:Q73599594-C6566707-E547-421C-BEBC-1B39DBDF9458 wds:Q73599594-C8D008BE-3CBD-4CCD-B9BE-982FE9141EDB wds:Q73599594-CD215413-B6BE-4DAC-A144-7E1F42A7C346 wds:Q73599594-94D1CC7E-6DC6-4985-97DA-2354F033B2D7 wds:Q73599594-A3BE80A8-9D33-475D-A307-4EED8FCE53DB wds:Q73599594-7FB72F07-1714-4393-8F5F-0A776B54DDED wds:Q73599594-8ACFD470-8D40-494B-A60C-929E65C7333F wds:Q73599594-5E15BB71-B108-4AF8-84B6-2892261B1BEF wds:Q73599594-5E4D5674-07A6-4152-8E40-E09B5CCC87B7 wds:Q73599594-64C87DEE-4F35-44BA-9358-96EC1698B073 wds:Q73599594-3AC0E0E1-40BC-4CCE-BD72-8D61D19678D1 wds:Q73599594-55331106-AE0D-45EA-B993-682966E0BFE2 wds:Q73599594-20C66D70-4832-49C7-9B3F-E08265856B8A wds:Q73599594-21FEEB5D-B6BF-4EB2-B954-77243256E5D3 wds:Q73599594-2540CF88-B72F-44FA-B9A1-09A32FA70E82 wds:Q73599594-39FEDFC2-63C9-4837-A246-F12D982B4153 wds:Q73599594-14BAF69C-2C7A-40AA-825C-147B8E3FB62F wds:Q73599594-ED7F8976-4682-4FC5-8DAB-267AFEF33E68 wds:Q73599594-F9FBC338-6BD0-46AD-8728-50466BFFB13F wds:Q73599594-E4812640-EA8F-4F38-B96C-BCA5FB9A9FC9 wds:Q73599594-E9454567-F24F-4044-8398-2C4741C988A1 wds:Q73599594-EBAD3270-99E7-4D5D-87F8-90FBE45C36EE wds:Q73599594-CD724199-25AD-4179-A9A0-CBF628A9DB09
wdt:P2860
wd:Q70485353 wd:Q72285055 wd:Q54022849 wd:Q28186187 wd:Q47315222 wd:Q73951493 wd:Q47808940 wd:Q59096013 wd:Q70532788 wd:Q69376431 wd:Q44612131 wd:Q71827452 wd:Q43765794 wd:Q37358508 wd:Q40518648 wd:Q74561883 wd:Q37019110 wd:Q34336722 wd:Q39781545 wd:Q46311150 wd:Q59065336 wd:Q67272972 wd:Q47295608 wd:Q72623669 wd:Q70401604
p:P2093
wds:Q73599594-DA1DC1AE-1FF8-4599-9237-79E07579D181 wds:Q73599594-8DCC73AA-EE1B-436C-B9E4-67F65DA7C23C wds:Q73599594-A74C6876-A8C6-4D6B-88E7-A14783B75669 wds:Q73599594-662E3180-3463-4906-9941-4BF6F6321275 wds:Q73599594-7B9E0184-FDAF-4CD3-BB3B-4A7CA81A436B wds:Q73599594-4FC8B4FF-BA52-4F38-81F2-07321BAD3F65
wdt:P2093
R E Jordan M A Mascelli L Damaraju H F Weisman S J Marciniak N S Kleiman
rdfs:label
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab
skos:prefLabel
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab
schema:name
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab
p:P1476
wds:Q73599594-DEE5AF1A-87AD-40E1-9590-BC2D7A07FF8D
wdt:P1476
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab
p:P304
wds:Q73599594-1A2D8A19-1DF7-49EB-89A6-10C170EB2691
wdt:P304
696-703
p:P31
wds:Q73599594-B11F8540-2C58-4053-AFCA-A11DFCA961CF
wdt:P31
wd:Q13442814
p:P921
wds:Q73599594-72BC797D-10E8-476A-AF7D-6142072260E1
wdt:P921
wd:Q190016
p:P698
wds:Q73599594-C468DBF3-2AB4-46FD-BAD2-3CF65EA5D252
wdtn:P698
n12:10740154
wdt:P698
10740154
p:P1433
wds:Q73599594-FC7C78A9-48CA-4AC1-8B88-BE75BFE529ED
wdt:P1433
wd:Q2227156
p:P433
wds:Q73599594-BDEC52DF-0975-4D27-AFAC-7B40F0DC1CC3
p:P478
wds:Q73599594-9694F0AF-39FB-499C-8035-EAEE6AECABD1
wdt:P433
4
wdt:P478
139
p:P356
wds:Q73599594-C9079562-E00A-4D11-A05B-DDE254DAE69B
wdtn:P356
n9:S0002-8703(00)90050-4
wdt:P356
10.1016/S0002-8703(00)90050-4